A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer
OBJECTIVES:
Primary
- To assess whether daily duloxetine hydrochloride (duloxetine) decreases average joint
pain in women with aromatase inhibitor-associated musculoskeletal syndrome (AIMSS), as
measured at 12 weeks by the modified Brief Pain Inventory Short Form (BPI-SF).
Secondary
- To assess whether daily duloxetine decreases worst joint pain in women with AIMSS, as
measured at 12 weeks by the modified BPI-SF.
- To assess whether daily duloxetine decreases pain interference in women with AIMSS, as
measured at 12 weeks by the modified BPI-SF.
- To investigate whether daily duloxetine improves functioning, pain, and stiffness in
the knees/hips according to the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) scale. (Exploratory)
- To investigate whether daily duloxetine improves function, pain, and stiffness in the
hands according to the Modified Score for the Assessment and Quantification of Chronic
Rheumatoid Affections of the Hands (M-SACRAH). (Exploratory)
- To investigate whether daily duloxetine improves functional quality of life as measured
by the Functional Assessment of Cancer Therapy-Endocrine Scale (FACT-ES). (Exploratory)
- To investigate whether daily duloxetine improves the proportion of patients reporting
changes for the better versus worst as measured by the Global Rating of Change Scale.
(Exploratory)
- To investigate whether daily duloxetine decreases analgesic use.
- To investigate whether daily duloxetine increases adherence to, and reduces the
discontinuation rate for, aromatase inhibitor (AI) therapy. (Exploratory)
- To assess whether patients receiving duloxetine as compared to placebo have improved
depression as measured by the Patient Health Questionnaire (PHQ-9) at Weeks 6 and 12.
(Exploratory)
- To explore the relationship between inherited variants in genes responsible for
duloxetine metabolism and activity (COMT, HTR3A, SLC6A2, SLC6A4, CYP1A2, CYP2D6) and
aromatase (CYP19A1) and change in pain with 12 weeks of treatment. (Exploratory)
- To explore the impact of treatment on serum inflammatory cytokine levels with 12 weeks
of treatment at baseline and 12 weeks. (Exploratory)
- To bank blood samples for future correlative analyses. (Exploratory)
OUTLINE: This is a multicenter study. Patients are stratified according to baseline pain
score (4-6 vs 7-10), and prior taxane use (yes vs no). Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days
1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
- Arm II: Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on
days 85-91.
Patients complete the modified Brief Pain Inventory Short Form (BPI-SF) questionnaire at
baseline and periodically during study treatment. Patients may also complete the Western
Ontario and McMaster Universities Osteoarthritis (WOMAC) scale, the Modified Score for the
Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH), the
Functional Assessment of Cancer Therapy-Endocrine Scale (FACT-ES), Global Rating of Change
Scale, and the patient Health Questionnaire (PHQ-9).
Patients undergo blood sample collection at baseline and periodically during treatment for
correlative studies, including biomarker and genetic studies.
After completion of study treatment, patients are followed up for 168 days.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Reduction in average joint pain according to BPI-SF assessed up to 12 weeks
12 weeks
No
N. Lynn Henry, MD, PhD
Principal Investigator
University of Michigan Cancer Center
United States: Federal Government
CDR0000730691
NCT01598298
February 2014
Name | Location |
---|